Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Pregnancy and Childbirth
Published in: BMC Pregnancy and Childbirth 1/2017

Open Access 01-12-2017 | Research article

Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial

Authors: Xiao Xu, Kimberly A. Yonkers, Jennifer Prah Ruger

Published in: BMC Pregnancy and Childbirth | Issue 1/2017

Login to get access

Abstract

Background

Substance use in pregnancy is associated with severe maternal and fetal morbidities and substantial economic costs. However, few studies have evaluated the cost-effectiveness of substance use treatment programs in pregnant women. The purpose of this study was to evaluate the economic impact of a behavioral intervention that integrated motivational enhancement therapy with cognitive behavioral therapy (MET-CBT) for treatment of substance use in pregnancy, in comparison with brief advice.

Methods

We conducted an economic evaluation alongside a clinical trial by collecting data on resource utilization and performing a cost minimization analysis as MET-CBT and brief advice had similar effects on clinical outcomes (e.g., alcohol and drug use and birth outcomes). Costs were estimated from the health care system’s perspective and included intervention costs, hospital facility costs, physician fees, and costs of psychotropic medications from the date of intake assessment until 3-month postpartum. We compared effects of MET-CBT on costs with those of brief advice using Wilcoxon rank sum tests.

Results

Although the integrated MET-CBT therapy had higher intervention cost than brief advice (median = $1297/participant versus $303/participant, p < 0.01), costs of care during the prenatal period, delivery, and postpartum period, as well as for psychotropic medications, were comparable between the two groups (all p values ≥ 0.55). There was no statistically significant difference in overall cost of care (median total cost = $26,993/participant for MET-CBT versus $27,831/participant for brief advice, p = 0.90).

Conclusions

The MET-CBT therapy and brief advice resulted in similar clinical outcomes and overall medical costs. Further research incorporating non-medical costs, targeting women with more severe substance use disorders, and evaluating the impact of MET-CBT on participants’ quality of life will provide additional insights.

Trial registration

ClinicalTrials.gov NCT00227903. Registered 27 September 2005.
Literature
1.
Shankaran S, Lester BM, Das A, Bauer CR, Bada HS, Lagasse L, et al. Impact of maternal substance use during pregnancy on childhood outcome. Semin Fetal Neonatal Med. 2007;12:143–50.CrossRefPubMedPubMedCentral
2.
Hudak ML, Tan RC, Committee On Drugs; Committee On Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129:e540–60.CrossRefPubMed
3.
4.
Quesada O, Gotman N, Howell HB, Funai EF, Rounsaville BJ, Yonkers KA. Prenatal hazardous substance use and adverse birth outcomes. J Matern Fetal Neonatal Med. 2012;25:1222–7.CrossRefPubMedPubMedCentral
5.
Rodriguez EM, Mofenson LM, Chang BH, Rich KC, Fowler MG, Smeriglio V, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS. 1996;10:273–82.CrossRefPubMed
6.
7.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31.CrossRefPubMedPubMedCentral
8.
Lupton C, Burd L, Harwood R. Cost of fetal alcohol spectrum disorders. Am J Med Genet C Semin Med Genet. 2004;127C:42–50.CrossRefPubMed
9.
Tuten M, Fitzsimons H, Chisolm MS, Nuzzo PA, Jones HE. Contingent incentives reduce cigarette smoking among pregnant, methadone-maintained women: results of an initial feasibility and efficacy randomized clinical trial. Addiction. 2012;107:1868–77.CrossRefPubMedPubMedCentral
10.
Wilson GB, McGovern R, Antony G, Cassidy P, Deverill M, Graybill E, et al. Brief intervention to reduce risky drinking in pregnancy: study protocol for a randomized controlled trial. Trials. 2012;13:174.CrossRefPubMedPubMedCentral
11.
Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol. 2003;101:374–9.PubMed
12.
Ruger JP, Lazar CM. Economic evaluation of drug abuse treatment and HIV prevention programs in pregnant women: a systematic review. Addict Behav. 2012;37:1–10.CrossRefPubMed
13.
Yonkers KA, Forray A, Howell HB, Gotman N, Kershaw T, Rounsaville BJ, et al. Motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice: a randomized trial for treatment of hazardous substance use in pregnancy and after delivery. Gen Hosp Psychiatry. 2012;34:439–49.CrossRefPubMedPubMedCentral
14.
Chang G, Wilkins-Haug L, Berman S, Goetz MA. The TWEAK: application in a prenatal setting. J Stud Alcohol. 1999;60:306–9.CrossRefPubMed
15.
Russell M, Martier SS, Sokol RJ, Mudar P, Jacobson S, Jacobson J. Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Am J Public Health. 1996;86:1435–9.CrossRefPubMedPubMedCentral
16.
Fals-Stewart W, O’Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol. 2000;68:134–44.CrossRefPubMed
17.
McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.CrossRefPubMed
18.
Xu X, Yonkers KA, Ruger JP. Costs of a motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice for pregnant substance users. PLoS One. 2014;9:e95264.CrossRefPubMedPubMedCentral
19.
Thomson Reuters. Red Book: Pharmacy’s Fundamental Reference (Red Book Drug Topics). 114th ed. Montvale, NJ: PDR Network, LLC; 2010.
20.
21.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22–33.PubMed
22.
Daley M, Argeriou M, McCarty D, Callahan Jr JJ, Shepard DS, Williams CN. The costs of crime and the benefits of substance abuse treatment for pregnant women. J Subst Abuse Treat. 2000;19:445–58.CrossRefPubMed
23.
Daley M, Shepard DS, Bury-Maynard D. Changes in quality of life for pregnant women in substance user treatment: developing a quality of life index for the addictions. Subst Use Misuse. 2005;40:375–94.CrossRefPubMed
24.
Jansson LM, Svikis D, Lee J, Paluzzi P, Rutigliano P, Hackerman F. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Ttreat. 1996;13:321–9.CrossRef
25.
Svikis DS, Golden AS, Huggins GR, Pickens RW, McCaul ME, Velez ML, et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend. 1997;45:105–13.CrossRefPubMed
26.
Daley M, Argeriou M, McCarty D, Callahan Jr JJ, Shepard DS, Williams CN. The impact of substance abuse treatment modality on birth weight and health care expenditures. J Psychoactive Drugs. 2001;33:57–66.CrossRefPubMed
27.
Svikis D, McCaul M, Feng T, Stuart M, Fox M, Stokes E. Drug dependence during pregnancy. Effect of an on-site support group. J Reprod Med. 1998;43:799–805.PubMed
28.
Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy. 2014;2014:906723.CrossRefPubMedPubMedCentral
29.
30.
Goler NC, Armstrong MA, Osejo VM, Hung YY, Haimowitz M, Caughey AB. Early start: a cost-beneficial perinatal substance abuse program. Obstet Gynecol. 2012;119:102–10.CrossRefPubMed
31.
Taillac C, Goler N, Armstrong MA, Haley K, Osejo V. Early start: an integrated model of substance abuse intervention for pregnant women. Perm J. 2007;11:5–11.CrossRefPubMedPubMedCentral
Metadata
Title
Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial
Authors
Xiao Xu
Kimberly A. Yonkers
Jennifer Prah Ruger
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2017
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-017-1260-5

Other articles of this Issue 1/2017

BMC Pregnancy and Childbirth 1/2017 Go to the issue

Research article

The meaning of labour pain: how the social environment and other contextual factors shape women’s experiences

Research article

Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial

Research article

Differences in spatial distributions of iron supplementation use among pregnant women and associated factors in Ethiopia: evidence from the 2011 national population based survey

Research article

“Nothing’s actually happened to me.”: the experiences of fathers who found childbirth traumatic

Research article

Institutional maternal and perinatal deaths: a review of 40 low and middle income countries

Research article

The decision delivery interval in emergency caesarean section and its associated maternal and fetal outcomes at a referral hospital in northern Tanzania: a cross-sectional study